The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
June 7, 2024
View Complete Issue         Table of Contents 2019 
Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
June 7, 2024 (Issue: 5074)
Givinostat (Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the DMD-causing mutation. It is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
Article code: 5074a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.